Prenetics Global Ltd

PRE
About the company

Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories.

Country: Hong KongPrice: $16.51Market Cap: $322.2M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

8 of 12 pass — Graham, Buffett, Lynch +1 more object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILFAILFAILFAILFAILFAILPASSFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-30

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Graham, Buffett, Lynch +1 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.03, IC: N/A
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.03
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities2.36
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.03
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.03
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDA
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.03
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0339; #886/4210 (top 21.0%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 4✗ 24▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / Book Value per Share1.3x
    ✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio1.3x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-17.5%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-17.5%, ROC=None
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Valuation Reasonableness
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-9.3%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=1.3x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low421% of trailing low ($3.92)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-14.37%; #4361/6340 (top 68.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.5289; #2773/6449 (top 43.0%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share1.77x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+457.6%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.0950; #4361/5247 (top 83.1%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-9.27%; #3201/4519 (top 70.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-21.75%; #4057/6202 (top 65.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy
    ✗BuffettPositive and growing
    FCF Positive and Growing$-29.9M
    ✗LynchPositive and growing
    Operating Cash Flow$-28.9M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-13.52%, ROA=-21.68%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-9.3%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive2/5 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-13.9%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency2/5 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-29.9M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-9.27%; #3201/4519 (top 70.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 1✗ 12▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 110.0% vs Rev: 40.8%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction$-0.15 (2020) -> $-3.71 (2024)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/5 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth40.8%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency2/4 years with positive EPS growth
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 27.5% -> 50.3%, operating margin -501.5% -> -157.2%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability6% pass✓ 5✗ 30▾

    15 of 16 flag PRE's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)0/6 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/6 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-36.0%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-157.2% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-27.2%
    ✗Lynch> 15%
    EBIT / Enterprise Value-17.5%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-17.5%, ROC=None
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-21.68%
    ✗PiotroskiROA > 0
    ROA Change YoY-24.68% -> -21.68% (delta: +3.00%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-13.52%, ROA=-21.68%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY40.6% -> 50.3%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-188.4%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-27.2%
    ✗Dreman> 12%
    Margin of SafetyP/B=1.3x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-46.0% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/5 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-157.2%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-27.2%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-501.5% (2022) -> -157.2% (2024)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 27.5% -> 50.3%, operating margin -501.5% -> -157.2%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-14.37%; #4361/6340 (top 68.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+7.21%; #2981/3702 (top 80.5%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-27.18%; #3848/5226 (top 73.6%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.3849; #4777/5884 (top 81.2%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years0/5 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts13% pass✓ 2✗ 13▾

    Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)✓TempletonPASS (4/8)✗SleepFAIL (0/6)✗AsnessFAIL (Rank #1714/2370 (Top 72.3%))✗NeffFAIL (0/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag PRE's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio2.36
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-36.5%
    ✗Buffett> 10%
    ROIC - WACC-46.5%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)
    ✗Greenblatt> 25%
    Current Ratio Change YoY2.37 -> 2.36
    ✗PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.09x -> 0.14x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities2.36
    ✓Dreman> 1.5
    Return on Invested Capital-21.6%
    ✗Munger> 15%
    ROIC (high and growing)FY2022: ROIC=-21.4%; FY2023: ROIC=-19.6%; FY2024: ROIC=-21.6%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/3 years above 12% (latest -21.6%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

Company Profile

Industry: Measuring and Control Equipment
SIC Sector: Measuring & Medical Instruments
Size: Small Cap($322.2M)
Revenue: $30.6M+40.8% YoY
Net Income: $46.3M+26.2% YoY

Financial Snapshot

Operating Margin-157.2%
Return on Equity-27.2%
Debt / Equity0.03
Current Ratio2.36
EPS (Diluted)$-3.71
Shares Retired−6.4%

Similar Companies

TMOTHERMO FISHER SCIENTIFIC INC.
$259.4B
DHRDANAHER CORP /DE/
$163.9B
WATWATERS CORP /DE/
$90.5B
AAGILENT TECHNOLOGIES, INC.
$49.0B

Shareholder Return

Fiscal 2024

Issued 6.4% of shares last year.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

MetricFY 2024
Sources
  • 20-F · 2025-04-30
FY 2023
Sources
  • 20-F · 2024-05-01
FY 2022
Sources
  • 20-F · 2023-05-01
FY 2021
Sources
  • 20-F · 2023-05-01
FY 2020
Sources
  • 20-F · 2023-05-01
Market Cap$322.2Mcurrent$63.1Mest.$3.1Best.$1.7Best.$1.5Best.
Revenue$30.6M↑41%$21.7M↑65%$13.2M↑5%$12.5M↓81%$65.2M
Operating Income-$48.1M↑7%-$51.9M↑21%-$66.0M↓17%-$56.7M↓5594%-$995.1K
Net Income-$46.3M↑26%-$62.7M↑67%-$190.5M↓9%-$174.0M↓8871%-$1.9M
EPS (Diluted)$-3.71↑34%$-5.58↓123%$-2.50↑79%$-11.92↓7847%$-0.15
Gross Margin50.3%↑24%40.6%↑48%27.5%↓4%28.7%↓29%40.4%
Operating Margin-157.2%↑34%-238.7%↑52%-501.5%↓11%-452.1%↓29513%-1.5%
ROE-27.2%↑11%-30.4%↑62%-80.3%↓285%43.4%↑794%-6.3%
Total Debt$5.8M↑144%$2.4M↓64%$6.6M↑26%$5.3M--
Shareholders' Equity$170.4M↓17%$206.4M↓13%$237.1M↑159%-$400.8M↓1393%$31.0M
Current Ratio2.36↓1%2.37↓44%4.23↑132%1.82—
Debt / Equity0.03↑195%0.01↓59%0.03↑313%-0.01—
Operating Cash Flow-$28.9M↓110%-$13.8M↓195%$14.5M↑8%$13.4M↑566%-$2.9M
Free Cash Flow-$29.9M↓112%-$14.1M↓247%$9.6M↑96%$4.9M↑185%-$5.7M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Measuring and Control Equipment

PRE vs Peers — Financial Grading

Revenue$30.6MBottom 25%
Net Income$46.3MBottom 25%
ROE-27.2%Bottom 25%
D/E0.03Top 25%
Op. Margin-157.2%Bottom 25%
Curr. Ratio2.36Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
THERMO FISHER SCIENTIFIC INC.TMO$259.4B$700.22$44.6B$6.7B12.6%0.7417.4%1.893/93/93/71/3F-Score 57/11
DANAHER CORP /DE/DHR$163.9B$233.02$24.6B$3.6B6.9%0.3519.1%1.873/94/92/71/3F-Score 54/11
WATERS CORP /DE/WAT$90.5B$460.25$3.2B$642.6M25.1%0.5525.4%1.731/94/91/70/3F-Score 45/11
AGILENT TECHNOLOGIES, INC.A$49.0B$173.96$6.9B$1.3B19.3%0.4521.3%1.962/95/93/71/3F-Score 55/11
ROPER TECHNOLOGIES INCROP$47.5B$479.98$7.9B$1.5B7.7%0.4728.3%0.522/93/93/70/3F-Score 64/11
COHERENT CORP.COHR$43.0B$218.15$5.8B$49.4M0.9%0.691.6%2.193/91/90/70/3F-Score 44/11
TERADYNE, INCTER$39.0B$249.55$3.2B$554.0M19.8%0.0720.4%1.752/96/94/71/3F-Score 66/11
ILLUMINA, INC.ILMN$31.3B$207.01$4.3B$850.0M31.2%0.7318.6%2.082/91/93/71/3F-Score 85/11